JP Morgan Chase’s Corvus Pharmaceuticals CRVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.06M | Sell |
141,986
-3,171
| -2% | -$44K | ﹤0.01% | 4157 |
|
|
2026
Q1 | $1.95M | Buy |
145,157
+114,502
| +374% | +$1.83M | ﹤0.01% | 4126 |
|
|
2025
Q4 | $236K | Sell |
30,655
-1,577
| -5% | -$12.4K | ﹤0.01% | 5450 |
|
|
2025
Q3 | $238K | Buy |
32,232
+1,812
| +6% | +$9.27K | ﹤0.01% | 5426 |
|
|
2025
Q2 | $122K | Buy |
30,420
+25,681
| +542% | +$93.4K | ﹤0.01% | 5516 |
|
|
2025
Q1 | $15.1K | Sell |
4,739
-19,716
| -81% | -$92.9K | ﹤0.01% | 6220 |
|
|
2024
Q4 | $131K | Sell |
24,455
-25,101
| -51% | -$187K | ﹤0.01% | 5649 |
|
|
2024
Q3 | $262K | Buy |
49,556
+40,404
| +441% | +$145K | ﹤0.01% | 5284 |
|
|
2024
Q2 | $16.7K | Sell |
9,152
-43,672
| -83% | -$81.4K | ﹤0.01% | 6178 |
|
|
2024
Q1 | $94K | Buy |
52,824
+52,145
| +7,680% | +$109K | ﹤0.01% | 5700 |
|
|
2023
Q4 | $1.2K | Sell |
679
-69,228
| -99% | -$101K | ﹤0.01% | 6808 |
|
|
2023
Q3 | $102K | Buy |
69,907
+68,706
| +5,721% | +$145K | ﹤0.01% | 5459 |
|
|
2023
Q2 | $2.75K | Hold |
1,201
| – | – | ﹤0.01% | 6288 |
|
|
2023
Q1 | $1K | Hold |
1,201
| – | – | ﹤0.01% | 6507 |
|
|
2022
Q4 | $1K | Sell |
1,201
-1,585
| -57% | -$1.4K | ﹤0.01% | 6390 |
|
|
2022
Q3 | $2K | Buy |
2,786
+818
| +42% | +$780 | ﹤0.01% | 6236 |
|
|
2022
Q2 | $2K | Sell |
1,968
-3,531
| -64% | -$4.33K | ﹤0.01% | 6275 |
|
|
2022
Q1 | $9K | Buy |
5,499
+1,396
| +34% | +$2.56K | ﹤0.01% | 6222 |
|
|
2021
Q4 | $10K | Buy |
+4,103
| New | +$15.9K | ﹤0.01% | 6333 |
|
|
2019
Q3 | – | Sell |
-66,687
| Closed | -$226K | – | 5750 |
|
|
2019
Q2 | $226K | Sell |
66,687
-100,434
| -60% | -$393K | ﹤0.01% | 4617 |
|
|
2019
Q1 | $673K | Sell |
167,121
-62,171
| -27% | -$262K | ﹤0.01% | 4039 |
|
|
2018
Q4 | $841K | Buy |
229,292
+111,779
| +95% | +$762K | ﹤0.01% | 3857 |
|
|
2018
Q3 | $1.01M | Buy |
117,513
+2,997
| +3% | +$30K | ﹤0.01% | 3913 |
|
|
2018
Q2 | $1.26M | Sell |
114,516
-103,681
| -48% | -$1.16M | ﹤0.01% | 3696 |
|
|
2018
Q1 | $2.52M | Sell |
218,197
-27,264
| -11% | -$258K | ﹤0.01% | 3101 |
|
|
2017
Q4 | $2.54M | Sell |
245,461
-70,739
| -22% | -$906K | ﹤0.01% | 3171 |
|
|
2017
Q3 | $5.11M | Sell |
316,200
-16,434
| -5% | -$227K | ﹤0.01% | 2558 |
|
|
2017
Q2 | $4.03M | Buy |
332,634
+178,658
| +116% | +$1.91M | ﹤0.01% | 2615 |
|
|
2017
Q1 | $3.2M | Sell |
153,976
-26,123
| -15% | -$409K | ﹤0.01% | 2734 |
|
|
2016
Q4 | $2.58M | Buy |
180,099
+15,199
| +9% | +$231K | ﹤0.01% | 2904 |
|
|
2016
Q3 | $2.71M | Sell |
164,900
-10,200
| -6% | -$147K | ﹤0.01% | 2618 |
|
|
2016
Q2 | $2.5M | Buy |
+175,100
| New | +$2.37M | ﹤0.01% | 2692 |
|
Other funds holding CRVS
O
ASP
VC
PA
DTC
JP Morgan Chase's CRVS Position: Q2 2026 in Review
JP Morgan Chase reduced its Corvus Pharmaceuticals (CRVS) stake by 2.2% in Q2 2026, selling an estimated $44K and leaving 141,986 shares worth $2.06M. The position accounts for ﹤0.01% of the portfolio, ranked #4157.
JP Morgan Chase first reported a position in CRVS in Q2 2016 and has held it in 32 quarters since. The position peaked at $5.11M in Q3 2017. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.
- JP Morgan Chase held 141,986 shares of Corvus Pharmaceuticals worth $2.06M as of Q2 2026.
- JP Morgan Chase sold 3,171 Corvus Pharmaceuticals shares in Q2 2026, an estimated $44K.
- Corvus Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4157 holding.
- JP Morgan Chase first reported a position in Corvus Pharmaceuticals in Q2 2016 and has held it in 32 quarters since.
- JP Morgan Chase's Corvus Pharmaceuticals position peaked at $5.11M in Q3 2017.
- 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.